AR032358A1 - Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamento - Google Patents
Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamentoInfo
- Publication number
- AR032358A1 AR032358A1 ARP010103460A ARP010103460A AR032358A1 AR 032358 A1 AR032358 A1 AR 032358A1 AR P010103460 A ARP010103460 A AR P010103460A AR P010103460 A ARP010103460 A AR P010103460A AR 032358 A1 AR032358 A1 AR 032358A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently represent
- cycloalkyl
- represent hydrogen
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto que se presenta por medio de la formula general (1) en la cual R1 representa hidrogeno, alquilo de C1-6, cicloalquilo, o cicloalquilalquilo; R2 y R3 en forma independiente representan hidrogeno, halogeno, alquilo de C1-6; cicloalquilo de C3-8, o cicloalquilo de C3-8-alquilo de C1-6 o R2 y R3 juntos forman un cicloalquilo de C3-8; R4, R5, R6 y R7 en forma independiente representan hidrogeno, halogeno CF3, NO2, CN1-6 alquilo, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-8, alcoxi de C1-6, C1-6-alquiltio, OH, SH, NR14R15, en los cuales R14 y R15 en forma independiente representan hidrogeno o alquilo de C1-6; -COR16 en los cuales R16 representa OH, alquilo C1-6, alcoxi de C1-6, NR17R18 en los cuales R17 y R18 en forma independiente representan hidrogeno o alquilo de C1-6; arilo o heteroarilo, en los cuales el arilo y el heteroarilo se sustituyen en forma opcional una o más veces con halogeno, CF3, OCF3, CH, NO2, alquilo de C1-6, alquenilo de C2-6, C2-6 alquinilo, cicloalquilo de C3-8, alcoxi de C1-6, tioalquilo de C1-6, OH, SH, NR24R25 en los cuales R24 y R25 en forma independiente representan hidrogeno o alquilo de C1-6; o R4 y R5, o R5 y R6 y R7 juntos forman un anillo fusionado, aromático, saturado o saturado en forma parcial, el cual contiene en forma opcional uno o más heteroátomos tales como O, N o S; R8, R9, R10, R11 y R12 en forma independiente representan hidrogeno, halogeno, CF3, OCF3, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo de C3-8, alcoxi de C1-6, alquiltio de C1-6, OH, SH, NR19R20, en los cuales R19 y R20 en forma independiente representan hidrogeno o alquilo de C1-6; o R8, R9, R10, R11 y R12 en forma independiente representan ûCOR21, en los cuales R21 representa OH, alcoxi de C1-6, NR22R23 en los cuales R22 y R23 en forma independiente representan hidrogeno o alquilo de C1-6; o R8, R9, R10 R11 y R12 en forma independiente representan arilo o heteroarilo, en los cuales el arilo y el heteroarilo se sustituyen en forma opcional uno o más veces con halogeno, CF3, OCF3, CH, NO2, alquilo de C1-6, alquenilo de C2-6 alquinilo C2-6, cicloalquilo de C3-8, alcoxi de C1-6, tioalquilo de C1-6, OH, SH, COR26, en los cuales R26 representa OH, alcoxi de C1-6 o alquilo de C1-6; o NR30R31, en los cuales R30 y R31 en forma independiente representan hidrogeno o alquilo de C1-6; R8 y R9, o R9, o R10, o R11, o R11 y R12 juntos forman un anillo fusionado aromático, saturado o saturado en forma parcial, el cual contiene en forma opcional uno o más heteroátomos tales como O, N o S; Y es O, S, CH2, o CH y cuando Y es CH entonces la línea de puntos es un enlace; n es 2, 3, 4, 5 o 6; Q representa C, P-OR29, o S=O, en el cual R29 representa hidrogeno o alquilo de C1-6 arilo o aril-alquilo de C1-65 en el cual el arilo se puede sustituir con halogeno, CF3, OCF3, CH, NO2 o alquilo C1-6; en forma opcional R27 y R28 juntos forman un anillo, el cual puede contener átomos de nitrogeno, oxígeno, o de sulfuro adicionales y el anillo puede ser saturado en forma parcial; R29 y R30 representa hidrogeno, alquilo de C1-6, un cicloalquilo, o un cicloalquilalquilo; o su sal de adicion aceptable para uso farmacéutico. Los compuestos son utiles como inhibidores del transporte de glicina y para el tratamiento de enfermedades responsables de la inhibicion del transportador de glicina. También se proporciona una composicion farmacéutica que comprende un compuesto de formula I como se definio anteriormente y el uso de compuestos para la manufactura de medicamentos para el tratamiento de enfermedades responsables a ligandos del transportador de glicina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001124 | 2000-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032358A1 true AR032358A1 (es) | 2003-11-05 |
Family
ID=8159626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103460A AR032358A1 (es) | 2000-07-21 | 2001-07-20 | Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamento |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6921774B2 (es) |
| EP (1) | EP1301502B1 (es) |
| JP (1) | JP2004504393A (es) |
| KR (1) | KR20030015889A (es) |
| CN (1) | CN100509791C (es) |
| AR (1) | AR032358A1 (es) |
| AT (1) | ATE295844T1 (es) |
| AU (2) | AU8174001A (es) |
| BG (1) | BG107530A (es) |
| BR (1) | BR0113011A (es) |
| CA (1) | CA2416447A1 (es) |
| CZ (1) | CZ2003396A3 (es) |
| DE (1) | DE60110914T2 (es) |
| EA (1) | EA005621B1 (es) |
| ES (1) | ES2238466T3 (es) |
| HR (1) | HRP20030053A2 (es) |
| HU (1) | HUP0302778A3 (es) |
| IL (2) | IL153988A0 (es) |
| IS (1) | IS6693A (es) |
| MX (1) | MXPA03000642A (es) |
| NO (1) | NO20030243L (es) |
| NZ (1) | NZ523720A (es) |
| PL (1) | PL364439A1 (es) |
| PT (1) | PT1301502E (es) |
| SK (1) | SK2022003A3 (es) |
| UA (1) | UA75081C2 (es) |
| WO (1) | WO2002008216A1 (es) |
| ZA (1) | ZA200300514B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006524642A (ja) * | 2003-04-30 | 2006-11-02 | ハー・ルンドベック・アクチエゼルスカベット | 芳香族オキシフェニルおよび芳香族スルファニルフェニル誘導体 |
| BRPI0413587A (pt) * | 2003-08-21 | 2006-10-17 | Lundbeck & Co As H | usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença |
| US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| EP1727785A1 (en) * | 2004-03-12 | 2006-12-06 | H.Lundbeck A/S | Phenyl indan derivatives |
| WO2005100301A1 (en) * | 2004-03-31 | 2005-10-27 | Eli Lilly And Company | 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors |
| WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| US8013018B2 (en) * | 2006-07-18 | 2011-09-06 | Astellas Pharma Inc. | Aminoindane derivative or salt thereof |
| CA2661863A1 (en) * | 2006-08-30 | 2008-03-06 | F. Hoffmann-La Roche Ag | Inhibitors for glyt-1 |
| US20100083581A1 (en) * | 2007-06-18 | 2010-04-08 | Mattice Douglas A | Environmental brush seal |
| DK3006024T3 (da) | 2009-01-20 | 2019-06-03 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Benzoesyre eller salte deraf til forstærkning af aktiviteten af et neurofarmaceutisk lægemiddel |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| US9700563B2 (en) * | 2012-09-06 | 2017-07-11 | MediSynergies, LLC | Kappa opioid receptor compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1166711A (en) * | 1966-03-28 | 1969-10-08 | Kefalas As | Process for the Preparation of Phenyl-Indane and -Tetralin Derivatives |
| US3549656A (en) | 1967-12-28 | 1970-12-22 | Kefalas As | Antidepressant 1 - aminoalkyl - thiophthalanes and acid addition salts thereof |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US5225323A (en) | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
| EP0614487A4 (en) | 1991-11-12 | 1995-04-19 | Synaptic Pharma Corp | DNA encoding a glycine transporter and applications therefor. |
| US5824486A (en) | 1996-05-31 | 1998-10-20 | Allelix Neuroscience Inc. | Glycine transporter-transfected cells and uses thereof |
| US6008015A (en) | 1997-04-11 | 1999-12-28 | Allelix Neuroscience Inc. | Glycine transporter |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6566550B2 (en) * | 2001-06-21 | 2003-05-20 | Pfizer Inc | Substituted aromatic ethers as inhibitors of glycine transport |
-
2001
- 2001-07-19 IL IL15398801A patent/IL153988A0/xx not_active IP Right Cessation
- 2001-07-19 AT AT01960184T patent/ATE295844T1/de not_active IP Right Cessation
- 2001-07-19 AU AU8174001A patent/AU8174001A/xx active Pending
- 2001-07-19 CA CA002416447A patent/CA2416447A1/en not_active Abandoned
- 2001-07-19 MX MXPA03000642A patent/MXPA03000642A/es not_active Application Discontinuation
- 2001-07-19 HU HU0302778A patent/HUP0302778A3/hu unknown
- 2001-07-19 PT PT01960184T patent/PT1301502E/pt unknown
- 2001-07-19 PL PL01364439A patent/PL364439A1/xx not_active Application Discontinuation
- 2001-07-19 ES ES01960184T patent/ES2238466T3/es not_active Expired - Lifetime
- 2001-07-19 DE DE60110914T patent/DE60110914T2/de not_active Expired - Fee Related
- 2001-07-19 AU AU2001281740A patent/AU2001281740B2/en not_active Ceased
- 2001-07-19 JP JP2002514122A patent/JP2004504393A/ja not_active Withdrawn
- 2001-07-19 EA EA200300180A patent/EA005621B1/ru not_active IP Right Cessation
- 2001-07-19 WO PCT/DK2001/000510 patent/WO2002008216A1/en not_active Application Discontinuation
- 2001-07-19 SK SK202-2003A patent/SK2022003A3/sk unknown
- 2001-07-19 CN CNB018158579A patent/CN100509791C/zh not_active Expired - Fee Related
- 2001-07-19 CZ CZ2003396A patent/CZ2003396A3/cs unknown
- 2001-07-19 EP EP01960184A patent/EP1301502B1/en not_active Expired - Lifetime
- 2001-07-19 NZ NZ523720A patent/NZ523720A/en unknown
- 2001-07-19 UA UA2003010452A patent/UA75081C2/uk unknown
- 2001-07-19 KR KR10-2003-7000851A patent/KR20030015889A/ko not_active Application Discontinuation
- 2001-07-19 BR BR0113011-0A patent/BR0113011A/pt not_active IP Right Cessation
- 2001-07-20 AR ARP010103460A patent/AR032358A1/es not_active Application Discontinuation
-
2003
- 2003-01-16 IL IL153988A patent/IL153988A/en unknown
- 2003-01-17 US US10/348,490 patent/US6921774B2/en not_active Expired - Fee Related
- 2003-01-17 NO NO20030243A patent/NO20030243L/no not_active Application Discontinuation
- 2003-01-20 IS IS6693A patent/IS6693A/is unknown
- 2003-01-20 ZA ZA200300514A patent/ZA200300514B/en unknown
- 2003-01-27 HR HR20030053A patent/HRP20030053A2/hr not_active Application Discontinuation
- 2003-02-05 BG BG107530A patent/BG107530A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032358A1 (es) | Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamento | |
| ECSP055867A (es) | Derivados de pirrolopirimidina | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| CO4950557A1 (es) | Compuestos y metodos | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR040230A1 (es) | Indol, azaindol, y heterociclos relacionados de 4-alquenil piperidina | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| CY1107966T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii | |
| PA8596101A1 (es) | Compuestos de triazol utiles en terapia | |
| PE20040949A1 (es) | DERIVADOS DE HEXAHIDRO-PIRAZINO [1,2-a] PIRIMIDIN-4,7-DIONA SUSTITUIDOS EN POSICION 3 POR NITROGENO Y PROCEDIMIENTO PARA LA PREPARACION DE LA COMPOSICION FARMACEUTICA | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| CO4970807A1 (es) | Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR092279A1 (es) | Pirrol carboxamidas fluorometilo sustituidas | |
| DE69131759D1 (de) | An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |